Glaucoma Drop Aids Part 2

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBoston Medical Center

About this trial

Glaucoma medications are vital to disease management and prevention of further loss of vision as over time glaucoma will lead to irreversible blindness. The average size of a glaucoma medication bottle is around 10cc and these medications when used 2-3 times daily are expected to last patients an entire month. The investigators found that at Boston Medical Center (BMC) a majority of Yawkey Eye Clinic patients are unable to deliver the drops into their eyes due to poor vision or difficulty squeezing drop bottles. These patients also often deliver more than a necessary amount leading to premature completion of the bottle. However, because the cost benefit ratio of these drop aids is unclear, they are not routinely offered to the patients. Although the efficacy of these drop aids has not been well studied, if effective, the cost of these drop aids would more than pay themselves by improving medication compliance and visual function of the patients. This study aims to determine the efficacy of the Nanodropper in the BMC Yawkey Eye Clinic patient population.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Currently on the same topical ophthalmic medications for treatment of glaucoma for a minimum of two months

Patient of Boston University Eye Associates

Disqualifiers

Changed glaucoma medications within the past 2 months

Trial design

Design model

Crossover

Treatments tested in this trial

  • Nanodropper

    Device

    The Nanodropper is the only FDA-listed, volume-reducing adaptor for eyedrop bottles. By twisting the Nanodropper onto a compatible bottle, the drop-size can be reduced by over 60%. Smaller drops have been shown to reduce waste, cost, and side effects.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Drop aid used then no drop aidExperimental treatment 1 intervention
Group B: No drop aid then drop aidExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Completion of topical ophthalmic drug bottle

This outcome will be measured in days by the patient from when a bottle is started until all the medication has been used.

Time frame
12 weeks
2

Satisfaction with dispensing opthalmic medication

An investigator developed survey completed by participants will be used to assess participants' satisfaction of eye drops with and without the drop aid.

Time frame
12 weeks

Secondary outcomes

1

Change in intraocular pressure with drop aid

An applanator will be used to measure the intraocular pressure during standard of care appointments.

Time frame
before starting the drop aid, after 6 weeks of using the drop aid

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Boston Medical Center

Lead sponsor

Boston Medical Center Patient Safety Grant

Collaborator

This trial is not recruiting at the moment. You can still explore other options: